Author Contributions
Conceptualization, X.W. and X.C.; methodology, X.W., X.C. and W.Z.; software, J.W. and C.Y.; validation, Z.F., X.M. and M.L.; formal analysis, X.C. and W.Z.; investigation, X.W. and X.C.; resources, X.Z. and Q.L.; data curation, X.M. and M.L.; writing—original draft, X.W., X.C. and W.Z.; writing—review and editing, X.C. and C.F.; visualization, X.W., X.C. and W.Z.; supervision, C.F. and Q.L.; project administration, X.Z. and Q.L.; funding acquisition, C.F. and Q.L. All authors have read and agreed to the published version of the manuscript.
Figure 1.
Antibody levels and heat stress detection. (A) Detection of antibody levels after NDV injection. (B) The chickens in the NC group were normal breathers. (C) The chickens in the heat stress (36 ± 1 °C) group showed mouth opening and rapid breathing. (D–F) The changes in H/L, concentration, and CD4+/CD8+ were detected after different treatments. Data presented as mean ± SEM. Blue arrow: The state of the chicken's mouth; *: p < 0.05; **: p < 0.01, ns: no significance.
Figure 1.
Antibody levels and heat stress detection. (A) Detection of antibody levels after NDV injection. (B) The chickens in the NC group were normal breathers. (C) The chickens in the heat stress (36 ± 1 °C) group showed mouth opening and rapid breathing. (D–F) The changes in H/L, concentration, and CD4+/CD8+ were detected after different treatments. Data presented as mean ± SEM. Blue arrow: The state of the chicken's mouth; *: p < 0.05; **: p < 0.01, ns: no significance.
Figure 2.
Differentially expressed genes among four contrasts. The spleen-sequencing data were subjected to grouping and comparison. The SP-NC is the control group, SP-IM is the vaccination group, and SP-IM. HS refers to the heat treatment vaccination groups (A,B). The sequencing data pertaining to the bursa of Fabricius were subjected to grouping and comparison. BU-NC is the control group, BU-IM is the vaccination group, BU-IM.HS refers to the heat treatment vaccination groups (C,D). (A,C): DEGs are unique or shared among the two contrasts; (B,D): DEGs are up or down in the latter of each contrast.
Figure 2.
Differentially expressed genes among four contrasts. The spleen-sequencing data were subjected to grouping and comparison. The SP-NC is the control group, SP-IM is the vaccination group, and SP-IM. HS refers to the heat treatment vaccination groups (A,B). The sequencing data pertaining to the bursa of Fabricius were subjected to grouping and comparison. BU-NC is the control group, BU-IM is the vaccination group, BU-IM.HS refers to the heat treatment vaccination groups (C,D). (A,C): DEGs are unique or shared among the two contrasts; (B,D): DEGs are up or down in the latter of each contrast.
Figure 3.
The biological processes of DEGs enrichment in different treatments. (A) GO enrichment analysis of DEGs in spleen samples. (B) Enriched biological processes included the assembly of cellular protein complexes, platelet activation, etc. (C) GO enrichment analysis of DEGs in the bursa of Fabricius samples. (D) Enrichment occurred in adhesion and cellular processes.
Figure 3.
The biological processes of DEGs enrichment in different treatments. (A) GO enrichment analysis of DEGs in spleen samples. (B) Enriched biological processes included the assembly of cellular protein complexes, platelet activation, etc. (C) GO enrichment analysis of DEGs in the bursa of Fabricius samples. (D) Enrichment occurred in adhesion and cellular processes.
Figure 4.
IPA network of differential gene enrichment. The 35 differentially expressed genes in Group B formed significantly interactive gene networks. Colored in green are down-regulated in White Leghorn. Color intensity correlates with the size of the FC, in which the color is darker, and the variance is greater.
Figure 4.
IPA network of differential gene enrichment. The 35 differentially expressed genes in Group B formed significantly interactive gene networks. Colored in green are down-regulated in White Leghorn. Color intensity correlates with the size of the FC, in which the color is darker, and the variance is greater.
Figure 5.
The expression detection of related genes after LPS-stimulated HD11. (A–H): Cells were collected for RNA extraction after being stimulated for 2 h, 4 h, and 8 h using 1 μg/mL of LPS; RT-qPCR was used to detect the expression level of related genes. NC is the control group, 2 h, 4 h, and 6 h are the stimulation times by LPS. The NC group is without LPS stimulation. Data presented as mean ± SEM, *: p< 0.05; **: p < 0.01.
Figure 5.
The expression detection of related genes after LPS-stimulated HD11. (A–H): Cells were collected for RNA extraction after being stimulated for 2 h, 4 h, and 8 h using 1 μg/mL of LPS; RT-qPCR was used to detect the expression level of related genes. NC is the control group, 2 h, 4 h, and 6 h are the stimulation times by LPS. The NC group is without LPS stimulation. Data presented as mean ± SEM, *: p< 0.05; **: p < 0.01.
Figure 6.
DUSP1 overexpression accelerates HD11 recognition of LPS and thus allows earlier LPS presentation. (A) Verification of DUSP1 overexpression efficiency. (B) RT-qPCR was used to detect antigen-passing-related genes after overexpression of DUSP1. (C–H) Overexpression of DUSP1 was followed by 1 μg/mL LPS stimulation for different times, followed by RT-qPCR to detect the expression of MHC-II, TLR4, IL1B, CD1C, CD80, and CD86.The NC group was only stimulated with LPS.Data presented as mean ± SEM, *: p< 0.05; **: p < 0.01.
Figure 6.
DUSP1 overexpression accelerates HD11 recognition of LPS and thus allows earlier LPS presentation. (A) Verification of DUSP1 overexpression efficiency. (B) RT-qPCR was used to detect antigen-passing-related genes after overexpression of DUSP1. (C–H) Overexpression of DUSP1 was followed by 1 μg/mL LPS stimulation for different times, followed by RT-qPCR to detect the expression of MHC-II, TLR4, IL1B, CD1C, CD80, and CD86.The NC group was only stimulated with LPS.Data presented as mean ± SEM, *: p< 0.05; **: p < 0.01.
Figure 7.
HD11 presentation of LPS is affected by DUSP1 expression levels. (A) Interference effect of DUSP1 interference fragment. (B–G): After interfering with DUSP1, 1 μg/mL LPS stimulation was given at different times, followed by RT-qPCR to detect the expression of MHC-I, MHC-II, CD80, CD86, CD1C, and IL6.The NC group was only stimulated with LPS. Data presented as mean ± SEM, *: p< 0.05; **: p < 0.01.
Figure 7.
HD11 presentation of LPS is affected by DUSP1 expression levels. (A) Interference effect of DUSP1 interference fragment. (B–G): After interfering with DUSP1, 1 μg/mL LPS stimulation was given at different times, followed by RT-qPCR to detect the expression of MHC-I, MHC-II, CD80, CD86, CD1C, and IL6.The NC group was only stimulated with LPS. Data presented as mean ± SEM, *: p< 0.05; **: p < 0.01.
Figure 8.
HSPA5 overexpression accelerates HD11 recognition of LPS and thus allows earlier LPS presentation. (A) Verification of HSPA5 overexpression efficiency. (B) Detection of antigen passing-related genes after overexpression of HSPA5. (C–J) Overexpression of HSPA5 was followed by 1 μg/mL LPS stimulation for different times, followed by RT-qPCR to detect the expression of MHC-I, MHC-II, CD80, CD86, CD1C, TLR4, IL1B, and IL6.The NC group was only stimulated with LPS.Data presented as mean ± SEM, *: p< 0.05; **: p < 0.01.
Figure 8.
HSPA5 overexpression accelerates HD11 recognition of LPS and thus allows earlier LPS presentation. (A) Verification of HSPA5 overexpression efficiency. (B) Detection of antigen passing-related genes after overexpression of HSPA5. (C–J) Overexpression of HSPA5 was followed by 1 μg/mL LPS stimulation for different times, followed by RT-qPCR to detect the expression of MHC-I, MHC-II, CD80, CD86, CD1C, TLR4, IL1B, and IL6.The NC group was only stimulated with LPS.Data presented as mean ± SEM, *: p< 0.05; **: p < 0.01.
Figure 9.
HD11 presentation of LPS is affected by HSPA5 expression levels. (A) Interference effect of HSPA5 interference fragment; (B–G): After interfering with HSPA5, 1 μg/mL LPS stimulation was given at different times, followed by RT-qPCR to detect the expression of MHC-I, MHC-II, CD1C, IL6, CD80, and TLR4. Data presented as mean ± SEM, *: p< 0.05; **: p < 0.01.
Figure 9.
HD11 presentation of LPS is affected by HSPA5 expression levels. (A) Interference effect of HSPA5 interference fragment; (B–G): After interfering with HSPA5, 1 μg/mL LPS stimulation was given at different times, followed by RT-qPCR to detect the expression of MHC-I, MHC-II, CD1C, IL6, CD80, and TLR4. Data presented as mean ± SEM, *: p< 0.05; **: p < 0.01.
Table 1.
The DEGs are associated with immune responses in the spleen and bursa of Fabricius.
Table 1.
The DEGs are associated with immune responses in the spleen and bursa of Fabricius.
Gene Symble | Gene Description | log2FC | p Value | padj | ↑or↓(Up or Down) |
---|
Group A | | | | | |
FGB | fibrinogen alpha chain | 2.52 | 7.77 × 10−6 | 0.0066 | ↑ |
FGA | fibrinogen beta chain | Inf | 2.31 × 10−11 | 5.89 × 10−8 | ↑ |
FGG | fibrinogen gamma chain | 5.02 | 7.60 × 10−10 | 1.46 × 10−6 | ↑ |
IGSF11 | immunoglobulin superfamily member 11 | 2.59 | 7.14 × 10−8 | 9.96 × 10−5 | ↑ |
ALDOB | aldolase B, fructose-bisphosphate | 6.11 | 1.29 × 10−6 | 0.0013 | ↑ |
APOB | apolipoprotein B (including Ag(x) antigen) | Inf | 2.08 × 10−7 | 0.00026 | ↑ |
Group B | | | | | |
GZMA | granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) | 2.12 | 6.52 × 10−13 | 2.5 × 10−9 | ↑ |
DUSP1 | dual specificity phosphatase 1 | −1.77 | 3.63 × 10−19 | 5.59 × 10−15 | ↓ |
FGB | fibrinogen beta chain | −2.29 | 8.22 × 10−5 | 0.024 | ↓ |
FGA | fibrinogen alpha chain | #NAME? | 1.55 × 10−10 | 3.98 × 10−7 | ↓ |
FGG | fibrinogen gamma chain | −4.40 | 7.31 × 10−7 | 0.00055 | ↓ |
GC | group-specific component (vitamin D binding protein) | #NAME? | 1.46 × 10−5 | 0.0068 | ↓ |
APOLD1 | apolipoprotein L domain containing 1 | −2.80 | 2.39 × 10−6 | 0.0015 | ↓ |
IGSF11 | immunoglobulin superfamily member 11 | −2.49 | 4.44 × 10−7 | 0.00038 | ↓ |
ALDOB | aldolase B, fructose-bisphosphate | −6.09 | 4.13 × 10−6 | 0.0023 | ↓ |
ADAMTS1 | ADAM metallopeptidase with thrombospondin type 1 motif, 1 | −1.40 | 5.84 × 10−10 | 9.97 × 10−7 | ↓ |
LOC396380 | glutathione transferase | −1.19 | 0.000123 | 0.032 | ↓ |
APOB | apolipoprotein B (including Ag(x) antigen) | #NAME? | 7.37 × 10−7 | 0.00055 | ↓ |
GVIN1 | GTPase, very large interferon inducible 1 | 1.38 | 1.81 × 10−6 | 0.0012 | ↑ |
CCL17 | chemokine (C-C motif) ligand 17 | −1.39 | 0.000165 | 0.039 | ↓ |
HSPA5 | heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) | −0.95 | 2.76 × 10−5 | 0.011 | ↓ |
Group C | | | | | |
CD69 | CD69 molecule | 3.51 | 1.9 × 10−8 | 1.06 × 10−5 | ↑ |
Group D | | | | | |
COL21A1 | collagen, type XXI, alpha 1 | −1.51 | 3.25 × 10−7 | 0.00054 | ↓ |
CD69 | CD69 molecule | −2.91 | 3.88 × 10−5 | 0.034 | ↓ |
HSP90AB1 | heat shock protein 90kDa alpha (cytosolic), class B member 1 | −0.71 | 3.89 × 10−8 | 8.23 × 10−5 | ↓ |
Table 2.
The enriched KEGG pathway of DEGs.
Table 2.
The enriched KEGG pathway of DEGs.
No. | Pathway | p Value |
---|
Group A | | |
1 | Complement and coagulation cascades | 0.001 |
2 | Carbon fixation in photosynthetic organisms | 0.018 |
3 | Vitamin digestion and absorption | 0.02 |
4 | Fructose and mannose metabolism | 0.022 |
5 | Pentose phosphate pathway | 0.022 |
6 | Methane metabolism | 0.025 |
7 | Fat digestion and absorption | 0.031 |
8 | Glycolysis/Gluconeogenesis | 0.043 |
Group B | | |
1 | Ovarian steroidogenesis | 0.0004 |
2 | Vitamin digestion and absorption | 0.002 |
3 | Glutathione metabolism | 0.009 |
4 | Cyanoamino acid metabolism | 0.013 |
5 | Complement and coagulation cascades | 0.019 |
6 | Taurine and hypotaurine metabolism | 0.019 |
7 | Chemokine signaling pathway | 0.039 |
Group D | | |
1 | Synaptic vesicle cycle | 0.025 |
2 | Protein digestion and absorption | 0.035 |
Table 3.
DEGs interaction network of IPA in four alignment groups.
Table 3.
DEGs interaction network of IPA in four alignment groups.
NO. | Network | Genes (Count) |
---|
Group A |
1 | cellular function and maintenance, hematological system development and function, cellular development | BCL3, BCL, CD40, ↑CD69, CD3E, IL4, EL1B, INPP5D, MS4A1, POU2AF1, RIPK2, STAT6, TGFB1, TLR3 (14) |
Group B |
1 | Nervous system development and function, cancer, cardiovascular system development and function | FOXO1, ↑GZMA (2) |
2 | cellular movement, hematological system development and function, immune cell trafficking | CCL4, CXCL3, ↓DUSP1, ELF4, IL6, IL10, TGFB2, TNF (8) |
Group C |
1 | cellular movement, cellular function and maintenance, behavior | ↓CA3, CCL15, CD59, ↑CD69, CTSG, ↓DCLK1, DCX, DRD2, GDNF, GRIN1, HDC, LAMC2, ↑MAP2, MAPK1, MBP, MME, ↑MMP7, MMP8, NTF4, PP1-C, SRC, ↑TAC1, TACR1, TFF2, TGFA, TRPV1, ↓TUBA1C (27) |
2 | Cell-to-cell signaling and interaction, digestive system development and function, hepatic system development and function | ↓FER1L6, HLX (2) |
Group D |
1 | Cell-to-cell signaling and interaction, cellular growth and proliferation, cellular movement | ABCB4, ACE, CALCA, ↓CD69, CNTF, CREM, CRH, CTSG, ↑ENPP2, FCER1A, GCG, GDNF, HDC, IL6, IL6R, MMP8, NFAT, NR4A1, SELE, ↓TAC1, TACR1, TFF2, TGFA, TH, TNF, TNFRSF11B, TNFSF13B, TRPV1 (28) |
Table 4.
RT-qPCR validation of DEGs.
Table 4.
RT-qPCR validation of DEGs.
Gene | Log2(FC)_RNA-seq | Log2(FC)_qPCR |
---|
Group A | | |
MYL1 | 6.852 | 3.321 |
SYT8 | 2.386 | 1.988 |
FGB | 2.519 | 1.769 |
ALDOB | 3.027 | 2.256 |
IGSF11 | 2.592 | 2.941 |
Group B | | |
DUSP1 | −1.768 | −1.145 |
GZMA | 2.118 | 1.586 |
CCL17 | −1.395 | −1.16 |
FGB | −2.286 | −1.539 |
ALDOB | −6.087 | −2.195 |
GGT1 | −1.127 | −1.041 |
HSPA5 | −0.952 | −1.233 |
IGSF11 | −2.489 | −1.615 |
Group C | | |
CD69 | 3.513 | 3.026 |
TAC1 | 7.934 | 4.075 |
MMP7 | 5.248 | 2.579 |
DCLK1 | −2.429 | −1.318 |
AADAT | −1.158 | −1.502 |
MYBPC1 | −3.555 | −1.852 |
Group D | | |
CD69 | −2.91 | −1.699 |
TAC1 | −7.333 | −2.133 |
ABCB1LB | 1.151 | 2.018 |
COL21A1 | −1.511 | −1.092 |
ENPP2 | 1.291 | 1.396 |
HSP90AB1 | −0.712 | −0.845 |